Pheast Therapeutics has treated the first patient in a phase 1 trial of PHST001, a novel macrophage checkpoint inhibitor for advanced solid tumors.

It binds both transmembrane and soluble TREM2, triggering a rise in CSF sTREM2. Single and multi-dose studies of the small ...

For one, microglia hovering around plaques—the type that express the most TREM2—reportedly become desensitized to stimulation ...

7; phase 3 to approval transition rates are 15 ... The constant region triggers effector functions (phagocytosis, cytolysis, or initiation of complement cascade followed by cell lysis) by linking ...

An international collaboration between four scientists from Mainz, Valencia, Madrid, and Zurich has published new research in ...

REM stages and one REM stage. Ideally, you repeatedly cycle through each stage. Learn how long each stage lasts.

A team has identified a previously unknown phase of the immune response. The results challenge long-standing assumptions about the process called 'T-cell priming'. These new insights have significant ...

REDWOOD CITY, CA, USA I April 14, 2025 I Pheast Therapeutics, a private biotechnology company developing novel therapies to unleash the power of macrophages ...

See what moon phase it is tonight and find out when you can see the rest of the moon phases for 2025. Today, April 17, 2025, the moon is 19 days old and is in the Waning Gibbous phase of its lunar ...

Lysosomes are membrane-bound organelles in cells that act as recycling centers—breaking down waste materials, damaged ...